AgroAmerica Supports Higher Education to Help Reduce Migration in Latin America
24.3.2021 14:00:00 EET | Business Wire | Press release
The Agribusiness food company, AgroAmerica, is sponsoring the 100K Innovation Fund grant competition for higher education projects aimed at universities in The United States, Central America and the Dominican Republic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210324005218/en/
The 100,000 Strong in the Americas Innovation Fund Grant Competition for higher education, promoted by the Bureau of Western Hemisphere Affairs of the U.S. Department of State and supported by AgroAmerica, the U.S. Embassy in Guatemala, and the NGO Partners of the Americas, aims to impulse education initiatives through innovative models of academic training and student exchange programs between the United States and Central America & Dominican Republic, beginning in January 2022. Institutions of higher education in the United States and Guatemala, El Salvador, Honduras, Costa Rica, Panama, Belize, Nicaragua, and the Dominican Republic are invited to submit their 100K grant proposals to Partners of the Americas at 100kstrongamericas.org/grants before August 2, 2021. (Photo: Business Wire)
The 100K Innovation Fund New Grant Competition is sponsored by the Bureau of Western Hemisphere Affairs of the U.S. Department of State and supported by AgroAmerica, the U.S. Embassy in Guatemala and the NGO Partners of the Americas. The 100K Fund will be awarded in 12 grants of $25,000 this year to support new higher education projects.
AgroAmerica is the second multinational company in Guatemala to join this public-private initiative. The company's CEO, Fernando Bolaños Valle, said that "it is with great enthusiasm that AgroAmerica joins the State Department as a strategic partner in this regional initiative, in an organic way, because of our shared values; building, through educational programs, a more prosperous future full of hope for our countries… we are convinced that the future of our continent depends on strategic investments like these, which will multiply prosperity for the United States, Guatemala and the region."
Javier Aguirre, corporate director of AgroAmerica, explained that the company donated funds to strengthen local capacities in the areas of climate change, human rights, natural resource management, sustainable agriculture, conservation and reforestation, environmental protection and sustainable businesses.
"The new 100K Strong Americas Innovation Fund partnerships, supported by AgroAmerica and the Department of State, will grow the number of students in the United States, Central America and the Dominican Republic, so working together, they will acquire valuable new skills and knowledge and grow our economies," said Julie Chung, acting assistant secretary of the Bureau of Western Hemisphere Affairs at the U.S. Department of State.
About the 100K Innovation Fund
The 100,000 Strong in the Americas Innovation Fund is the public-private sector collaboration between the Department of State, U.S. embassies and Partners of the Americas to promote a positive agenda for the region by harnessing the power of education.
About AgroAmerica
AgroAmerica is an agribusiness company dedicated to the production and commercialization of food products, through the use of sustainable and responsible cultivation methods. It operates in Europe, the United States, Mexico, Guatemala, Ecuador, Peru, and Panama. The Company's Corporate Sustainability Strategy aims to generate value and balance between economic growth, natural resource conservation, and the wellbeing of customers, employees, and stakeholders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005218/en/
Contact information
Javier Aguirre
Corporate Director
comunicacion@agroamerica.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom